Literature DB >> 29954247

The C-terminal p6 domain of the HIV-1 Pr55Gag precursor is required for specific binding to the genomic RNA.

Noé Dubois1, Keith K Khoo2,3, Shannon Ghossein2,3, Tanja Seissler1, Philippe Wolff1,4, William J McKinstry3, Johnson Mak2,5, Jean-Christophe Paillart1, Roland Marquet1, Serena Bernacchi1.   

Abstract

The Pr55Gag precursor specifically selects the HIV-1 genomic RNA (gRNA) from a large excess of cellular and partially or fully spliced viral RNAs and drives the virus assembly at the plasma membrane. During these processes, the NC domain of Pr55Gag interacts with the gRNA, while its C-terminal p6 domain binds cellular and viral factors and orchestrates viral particle release. Gag∆p6 is a truncated form of Pr55Gag lacking the p6 domain usually used as a default surrogate for wild type Pr55Gag for in vitro analysis. With recent advance in production of full-length recombinant Pr55Gag, here, we tested whether the p6 domain also contributes to the RNA binding specificity of Pr55Gag by systematically comparing binding of Pr55Gag and Gag∆p6 to a panel of viral and cellular RNAs. Unexpectedly, our fluorescence data reveal that the p6 domain is absolutely required for specific binding of Pr55Gag to the HIV-1 gRNA. Its deletion resulted not only in a decreased affinity for gRNA, but also in an increased affinity for spliced viral and cellular RNAs. In contrast Gag∆p6 displayed a similar affinity for all tested RNAs. Removal of the C-terminal His-tag from Pr55Gag and Gag∆p6 uniformly increased the Kd values of the RNA-protein complexes by ~ 2.5 fold but did not affect the binding specificities of these proteins. Altogether, our results demonstrate a novel role of the p6 domain in the specificity of Pr55Gag-RNA interactions, and strongly suggest that the p6 domain contributes to the discrimination of HIV-1 gRNA from cellular and spliced viral mRNAs, which is necessary for its selective encapsidation.

Entities:  

Keywords:  HIV-1; Pr55Gag; RNA-protein binding specificity; fluorescence spectroscopy; genomic RNA; p6 domain

Mesh:

Substances:

Year:  2018        PMID: 29954247      PMCID: PMC6161697          DOI: 10.1080/15476286.2018.1481696

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  80 in total

1.  Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function.

Authors:  Dimiter G Demirov; Akira Ono; Jan M Orenstein; Eric O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Expression and purification of soluble recombinant full length HIV-1 Pr55(Gag) protein in Escherichia coli.

Authors:  William J McKinstry; Marcel Hijnen; Hanumant S Tanwar; Lindsay G Sparrow; Sureshbabu Nagarajan; Son T Pham; Johnson Mak
Journal:  Protein Expr Purif       Date:  2014-05-06       Impact factor: 1.650

3.  A non-cleavable hexahistidine affinity tag at the carboxyl-terminus of the HIV-1 Pr55Gag polyprotein alters nucleic acid binding properties.

Authors:  Maria C Bewley; Lisa Reinhart; Matthew S Stake; Shorena Nadaraia-Hoke; Leslie J Parent; John M Flanagan
Journal:  Protein Expr Purif       Date:  2016-10-06       Impact factor: 1.650

4.  Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switch.

Authors:  Siddhartha A K Datta; Zhuojun Zhao; Patrick K Clark; Sergey Tarasov; Jerry N Alexandratos; Stephen J Campbell; Mamuka Kvaratskhelia; Jacob Lebowitz; Alan Rein
Journal:  J Mol Biol       Date:  2006-10-26       Impact factor: 5.469

5.  Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain.

Authors:  Vineela Chukkapalli; Seung J Oh; Akira Ono
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

6.  In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain.

Authors:  S Campbell; A Rein
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.

Authors:  A Lever; H Gottlinger; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  The thermodynamics of Pr55Gag-RNA interaction regulate the assembly of HIV.

Authors:  Hanumant S Tanwar; Keith K Khoo; Megan Garvey; Lynne Waddington; Andrew Leis; Marcel Hijnen; Tony Velkov; Geoff J Dumsday; William J McKinstry; Johnson Mak
Journal:  PLoS Pathog       Date:  2017-02-21       Impact factor: 6.823

9.  Dynamic Association between HIV-1 Gag and Membrane Domains.

Authors:  Ian B Hogue; G Nicholas Llewellyn; Akira Ono
Journal:  Mol Biol Int       Date:  2012-07-05

10.  HIV controls the selective packaging of genomic, spliced viral and cellular RNAs into virions through different mechanisms.

Authors:  Laurent Houzet; Jean Christophe Paillart; Fatima Smagulova; Stephan Maurel; Zakia Morichaud; Roland Marquet; Marylène Mougel
Journal:  Nucleic Acids Res       Date:  2007-04-10       Impact factor: 16.971

View more
  16 in total

Review 1.  RNA Packaging in HIV.

Authors:  Alan Rein
Journal:  Trends Microbiol       Date:  2019-05-10       Impact factor: 17.079

2.  HIV-1 Gag protein with or without p6 specifically dimerizes on the viral RNA packaging signal.

Authors:  Samantha Sarni; Banhi Biswas; Shuohui Liu; Erik D Olson; Jonathan P Kitzrow; Alan Rein; Vicki H Wysocki; Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2020-08-13       Impact factor: 5.157

3.  Nucleic acid-induced dimerization of HIV-1 Gag protein.

Authors:  Huaying Zhao; Siddhartha A K Datta; Sung H Kim; Samuel C To; Sumit K Chaturvedi; Alan Rein; Peter Schuck
Journal:  J Biol Chem       Date:  2019-09-30       Impact factor: 5.157

4.  Zinc Fingers in HIV-1 Gag Precursor Are Not Equivalent for gRNA Recruitment at the Plasma Membrane.

Authors:  Emmanuel Boutant; Jeremy Bonzi; Halina Anton; Maaz Bin Nasim; Raphael Cathagne; Eléonore Réal; Denis Dujardin; Philippe Carl; Pascal Didier; Jean-Christophe Paillart; Roland Marquet; Yves Mély; Hugues de Rocquigny; Serena Bernacchi
Journal:  Biophys J       Date:  2020-06-12       Impact factor: 4.033

5.  A purine loop and the primer binding site are critical for the selective encapsidation of mouse mammary tumor virus genomic RNA by Pr77Gag.

Authors:  Akhil Chameettachal; Valérie Vivet-Boudou; Fathima Nuzra Nagoor Pitchai; Vineeta N Pillai; Lizna Mohamed Ali; Anjana Krishnan; Serena Bernacchi; Farah Mustafa; Roland Marquet; Tahir A Rizvi
Journal:  Nucleic Acids Res       Date:  2021-05-07       Impact factor: 16.971

Review 6.  How HIV-1 Gag Manipulates Its Host Cell Proteins: A Focus on Interactors of the Nucleocapsid Domain.

Authors:  Jéromine Klingler; Halina Anton; Eléonore Réal; Manon Zeiger; Christiane Moog; Yves Mély; Emmanuel Boutant
Journal:  Viruses       Date:  2020-08-13       Impact factor: 5.048

7.  Specific inter-domain interactions stabilize a compact HIV-1 Gag conformation.

Authors:  Chen Lin; Paola Mendoza-Espinosa; Ioulia Rouzina; Orlando Guzmán; José Antonio Moreno-Razo; Joseph S Francisco; Robijn Bruinsma
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

8.  Purification and Functional Characterization of a Biologically Active Full-Length Feline Immunodeficiency Virus (FIV) Pr50Gag.

Authors:  Anjana Krishnan; Vineeta N Pillai; Akhil Chameettachal; Lizna Mohamed Ali; Fathima Nuzra Nagoor Pitchai; Saeed Tariq; Farah Mustafa; Roland Marquet; Tahir A Rizvi
Journal:  Viruses       Date:  2019-07-27       Impact factor: 5.048

Review 9.  Overview of the Nucleic-Acid Binding Properties of the HIV-1 Nucleocapsid Protein in Its Different Maturation States.

Authors:  Assia Mouhand; Marco Pasi; Marjorie Catala; Loussiné Zargarian; Anissa Belfetmi; Pierre Barraud; Olivier Mauffret; Carine Tisné
Journal:  Viruses       Date:  2020-09-29       Impact factor: 5.048

Review 10.  The Interplay between ESCRT and Viral Factors in the Enveloped Virus Life Cycle.

Authors:  Bo Meng; Andrew M L Lever
Journal:  Viruses       Date:  2021-02-20       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.